CION Ameerpet
Targeted therapy aims at a specific molecular feature of the lymphoma cell rather than affecting all dividing cells. This guide explains how targeted drugs and the BTK-inhibitor class work, their side effects, and who they suit — with care guided by molecular testing at CION.
Targeted therapy is a family of lymphoma treatments built around a specific molecular feature of the cancer cell — a protein on its surface, a signalling enzyme inside it, or a growth pathway it depends on. Instead of broadly attacking all fast-dividing cells the way traditional chemotherapy does, targeted drugs are designed to interfere with one particular mechanism the lymphoma relies on. That precision is why these are sometimes called "targeted drugs" for lymphoma, and it can change the pattern of side effects a patient experiences.
Because targeted therapy is defined by the cancer's biology, it almost always follows molecular and genetic testing that confirms the relevant target is actually present. A well-known example is the BTK-inhibitor class, oral drugs that switch off a B-cell survival signal. Targeted therapy sits alongside — and is often combined with — chemotherapy, antibody-based immunotherapy and radiation as part of a coordinated plan.
This guide explains how targeted drugs work, how they differ from chemotherapy, their side effects and who they suit. For the full picture of lymphoma care, see our Lymphoma hub and our Lymphoma Treatment in Hyderabad page.
The discovery that certain B-cell lymphomas depend on B-cell receptor signalling led to the BTK-inhibitor class of targeted drugs, which block Bruton's tyrosine kinase — an enzyme in that signalling chain. This is a clear example of how identifying a molecular dependency in the lymphoma cell creates a precise drug target rather than a broad one. (Source: mechanism of B-cell receptor–pathway targeting, as summarised in NCCN and ESMO lymphoma guidelines.)
Targeted therapy is grouped by mechanism — what part of the cancer cell it acts on. These are drug classes, not brand names; the exact medicine and schedule are chosen individually by the treating team.
Some B-cell lymphomas rely on a constant "survive and grow" signal from the B-cell receptor. Drugs in the BTK-inhibitor class block Bruton's tyrosine kinase, an enzyme in that signalling chain, cutting off the message. These are typically taken as tablets and used in specific B-cell subtypes.
Lymphoma cells often carry distinctive surface proteins such as CD20 or CD30. Antibody-based treatments latch onto these markers to flag or attack the cell. This overlaps with antibody immunotherapy and is a cornerstone of many B-cell lymphoma regimens.
Certain lymphomas over-produce proteins that stop cells from dying when they should. Targeted drugs in this group counter that survival signal, nudging the cancer cell back toward its natural self-destruct pathway — used when the relevant molecular features are found.
Some targeted drugs are matched to specific genetic findings — such as cell-of-origin classification or particular gene rearrangements identified on testing. This is why cell-of-origin and double-hit testing is done before treatment, in line with NCCN and ESMO guidance.
Descriptions are by drug class and mechanism only. The specific medicine, dose and combination are decided individually by the treating team and are discussed on the treatment page.
Targeted therapy only helps when the lymphoma actually carries the target the drug is designed for — so getting the diagnosis and the molecular work-up right is everything. At CION, targeted therapy is never started from a scan alone.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Want to understand whether targeted drugs or a BTK inhibitor could fit your lymphoma subtype? CION's medical oncology and haematology team will review your reports and explain your options clearly.
Both are systemic (whole-body) treatments, but they work in very different ways. Understanding the difference helps set realistic expectations.
| Feature | Chemotherapy | Targeted therapy |
|---|---|---|
| How it works | Damages rapidly dividing cells broadly | Acts on one specific molecular target or pathway |
| Selectivity | Affects some healthy fast-dividing tissue too | More selective; may spare more normal cells |
| Typical route | Often by infusion in cycles | Many are oral tablets taken at home |
| Needs a test first? | Guided mainly by subtype and stage | Usually needs a confirmed molecular target |
| Common effects | Hair loss, low counts, nausea | Varies by class: fatigue, diarrhoea, rash, count or rhythm changes |
This is a general comparison; targeted therapy is not automatically "gentler" and is often combined with chemotherapy or antibody therapy rather than replacing it. Effects vary by individual.
Targeted therapy is only useful when the lymphoma carries the molecular target the drug acts on. Deciding whether it fits follows a clear sequence.
A biopsy and expert pathology review confirm the exact lymphoma subtype. Surface markers such as CD20 and CD30 are checked, because they point to which antibody-directed or targeted approaches may apply.
Deeper molecular and genetic testing — including cell-of-origin classification and testing for gene rearrangements such as MYC and BCL2 ("double-hit" lymphoma) — identifies specific targets and vulnerabilities. NCCN and ESMO guidelines tie many targeted options to these findings.
The multidisciplinary tumour board weighs the subtype, molecular results, stage and your overall health to decide whether targeted therapy is used alone, combined with other treatment, or held in reserve — for example in the relapsed or refractory setting.
Because each drug class acts on a different pathway, side effects differ between them. Many targeted drugs are taken continuously at home, so a steady routine and prompt reporting of new symptoms matter. Things the team watches for include:
CION's medical oncology team manages targeted therapy directly, reviews blood tests, and adjusts the dose when needed. For broader guidance, see managing lymphoma treatment side effects and what to expect during an infusion.
Outcomes in lymphoma are generally encouraging and vary a lot by subtype. In published series, Hodgkin lymphoma carries roughly 80–90% long-term survival, while diffuse large B-cell lymphoma (a common aggressive non-Hodgkin type) is often cited around 60–70% — figures that continue to improve as targeted and antibody-based options expand. These are population averages: your own outlook depends on subtype, stage, molecular features and response. (Source: published survival series referenced in NCCN and ESMO lymphoma guidelines; figures vary by individual.)
Targeted therapy is one tool among several, and it is often combined or sequenced with other treatments rather than used alone:
If your lymphoma may involve advanced cellular treatment, CAR T-cell therapy and stem-cell transplant are coordinated through accredited partner facilities. To discuss your options, book a free consultation or call 18002028726.
Get a free written second opinion from CION's lymphoma tumour board — especially valuable if molecular and genetic testing has not yet been arranged on your biopsy.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Targeted therapy is a group of lymphoma treatments designed to home in on a specific feature of the cancer cell — a protein on its surface, a signalling switch inside it, or a molecular pathway it depends on to grow. Unlike traditional chemotherapy, which affects many rapidly dividing cells, targeted drugs are built around a particular marker or mechanism, which can mean a different side-effect profile. Because targeted therapy is defined by the cancer's biology, it usually follows molecular and genetic testing that confirms the target is present. It is one of several tools used alongside chemotherapy, antibody-based immunotherapy and radiation. Your exact plan is decided by the tumour board — see Lymphoma Treatment in Hyderabad.
A BTK inhibitor is a class of oral targeted drug that blocks Bruton's tyrosine kinase (BTK), an enzyme that certain B-cell lymphomas rely on for a survival signal. By switching off this signalling pathway, the drug class starves those lymphoma cells of a growth message rather than poisoning all dividing cells. BTK inhibitors are typically taken as tablets and are mainly used in specific B-cell lymphoma subtypes. Whether a BTK inhibitor is suitable depends on the exact subtype and on molecular findings, which is why accurate subtyping matters first. CION describes therapy by drug class and mechanism; specific medicine names and regimens are set individually by the treating team and discussed on the treatment page.
Chemotherapy works broadly — it damages cells that divide quickly, which includes lymphoma but also some healthy tissues, producing familiar effects such as hair loss and low blood counts. Targeted therapy is more selective: it is aimed at a defined molecular target that the lymphoma depends on, so it may spare more normal cells and can have a different pattern of side effects. Many targeted drugs in lymphoma are taken as tablets at home rather than by infusion. That said, targeted therapy is not automatically "gentler" and is not right for every lymphoma — it only works when the target is present. In practice, targeted drugs are often combined with, or sequenced after, chemotherapy and antibody therapy rather than replacing them.
Targeted therapy is used across several B-cell and some T-cell lymphoma subtypes, but eligibility is driven by biology, not the label alone. Some slow-growing (indolent) B-cell lymphomas respond well to pathway-blocking targeted drugs; certain aggressive subtypes may be candidates when specific molecular features — such as cell-of-origin classification or particular gene rearrangements — are found. This is exactly why molecular and genetic testing (including cell-of-origin and double-hit testing) is done before treatment. NCCN and ESMO guidelines link many targeted options to defined markers. If a target is not present, other approaches — chemotherapy, immunotherapy or radiation — are used instead.
Side effects vary by drug class because each targets a different pathway. Broadly, oral targeted drugs can cause fatigue, diarrhoea or other digestive upset, rash, and changes in blood counts; some classes carry a risk of bleeding, irregular heart rhythm, high blood pressure, or increased infection risk, so monitoring blood tests and regular reviews are part of the plan. Because many are taken continuously at home, sticking to the schedule and reporting new symptoms promptly is important. CION's medical oncology team manages targeted therapy directly, monitors for these effects, and adjusts the dose when needed. General infusion-day and side-effect guidance is covered on managing side effects and what to expect during an infusion.
Usually, yes. Targeted therapy only helps when the cancer actually carries the target the drug is designed for, so confirming that target through molecular and genetic testing is a key step. Depending on the subtype, this can include immunohistochemistry for surface markers, cell-of-origin classification, and testing for specific gene rearrangements (for example MYC and BCL2 in "double-hit" lymphoma). These results tell the team whether a targeted approach is appropriate and how it should be combined or sequenced with other treatments. At CION, this testing is arranged on the biopsy tissue and every result is reviewed by the multidisciplinary tumour board before a plan is finalised, in line with NCCN and ESMO guidance.
Yes. CION's medical oncology and haematology team delivers targeted therapy and antibody-based treatment directly at our Hyderabad centres, alongside chemotherapy, radiation (IMRT), biopsy, bone-marrow evaluation and molecular testing. Some advanced cellular treatments such as CAR T-cell therapy and stem-cell transplant are coordinated through accredited partner facilities when they are the right option. Every targeted-therapy decision is made by the tumour board after subtyping and molecular testing, not from a scan alone. To discuss whether targeted drugs suit your lymphoma, see our lymphoma doctors or book a free consultation.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.